

Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 21, Number 1, 2000

Contents

Call for Papers

v

Original Articles

DENNIS O. DIXON AND STEPHEN W. LAGAKOS

Should Data and Safety Monitoring Boards Share Confidential Interim Data?

1

BONNIE A. FIJAL, JEFF M. HALL, AND JOHN S. WITTE

Clinical Trials in the Genomic Era: Effects of Protective Genotypes on Sample Size and Duration of Trial

7

GREG SCHWEMER

General Linear Models for Multicenter Clinical Trials

21

CHRISTINE BOUCHET, FRANCIS GUILLEMIN, AGNÈS PAUL-DAUPHIN,

AND SERGE BRIANÇON

Selection of Quality-of-Life Measures for a Prevention Trial:

A Psychometric Analysis

30

SCOTT A. HAMILTON

Dynamically Allocating Treatment When the Cost of Goods Is High and Drug Supply Is Limited

44

Commentary

DAVID L. DEMETS

Relationships Between Data Monitoring Committees

54

Book Reviews

56

Design Paper

BRIAN F. JOHNSON, GLENYS HAMILTON, JANIS FINK, GAIL LUCEY,

NANCY BENNET AND ROBERT LEW

A Design for Testing Interventions to Improve Adherence Within a Hypertension Clinical Trial

62

List of Reviewers

73

Volume 21, Number 2, 2000

Original Articles

A. S. WALKER, A. G. BABIKER, AND J. H. DARBYSHIRE

Analysis of Multivariate Failure-time Data from HIV Clinical Trials

75

DENNIS W. KING AND RODERICK LASHLEY

A Quantifiable Alternative to Double Data Entry

94

DONATELLA DE AMICI, CATHERINE KLERSY, FELICE RAMAJOLI, LORETTA BRUSTIA, AND PIERLUIGI POLITI	
Impact of the Hawthorne Effect in a Longitudinal Clinical Study: The Case of Anesthesia	103
DEBASHIS GHOSH	
Methods for Analysis of Multiple Events in the Presence of Death	115
BRIAN L. WIENS AND BORIS IGLEWICZ	
Design and Analysis of Three Treatment Equivalence Trials	127
Commentary	
RICK CHAPPELL	
Student Scholarship Competition Manuscripts: Relevance, Rigor, and Promise	138
Book Review	140
Design Paper	
ARTHUR V. PETERSON JR., SUE L. MANN, KATHLEEN A. KEALEY, AND PATRICK M. MAREK	
Experimental Design and Methods for School-Based Randomized Trials: Experience from the Hutchinson Smoking Prevention Project (HSPP)	144
 Volume 21, Number 2S, 2000 Supplement	
Letter from the President	1S
Calendar of Program	7S
Abstracts: Twenty-first Annual Meeting of the Society for Clinical Trials	43S
Author Index	137S
 Volume 21, Number 3, 2000	
Original Articles	
JOHN M. LACHIN	
Statistical Considerations in the Intent-to-Treat Principle	167
DAVID M. REBOUSSIN, DAVID L. DEMETS, KYUNGMAAN KIM, AND K. K. GORDON LAN	
Computations for Group Sequential Boundaries Using the Lan-DeMets Spending Function Method	190
THOMAS D. COOK	
Adjusting Survival Analysis for the Presence of Unadjudicated Study Events	208
ALEXANDRA Y. KRUSE, LISE L. KJAERGARD, KIM KROGSGAARD, CHRISTIAN GLUUD, ERIK L. MORTENSEN, ADAM GOTTSCHAU, ANDERS M. BJERG, AND THE INFO TRIAL GROUP	
A Randomized Trial Assessing the Impact of Written Information on Outpatients' Knowledge About and Attitude Toward Randomized Clinical Trials	223

Commentary

COLIN B. BEGG

Ruminations on the Intent-to-Treat Principle

241

Design Papers

JOHN R. A. RIGG, KONRAD JAMROZIK, PAUL S. MYLES, BRENDAN SILBERT,
PHILIP PEYTON, RICHARD W. PARSONS, AND KAREN COLLINS FOR THE
MASTER TRIAL STUDY GROUP

Design of the Multicenter Australian Study of Epidural Anesthesia and Analgesia
in Major Surgery: The MASTER Trial

244

DAVID M. HERRINGTON, DAVID M. REBOUSSIN, KAREN POTVIN KLEIN,
PENNY C. SHARP, SALLY A. SHUMAKER, THOMAS E. SNYDER,
AND KIM R. GEISINGER FOR THE ERA INVESTIGATORS

The Estrogen Replacement and Atherosclerosis (ERA) Study: Study Design and
Baseline Characteristics of the Cohort

257

RONALD J. PRINZ, JEAN E. DUMAS, EMILIE P. SMITH,
AND JAMES E. LAUGHLIN

The EARLY ALLIANCE Prevention Trial: A Dual Design to Test Reduction of
Risk for Conduct Problems, Substance Abuse, and School Failure in Childhood

286

Call For Papers

303

Volume 21, Number 4, 2000

Original Articles

ROBERT P. McMAHON AND FRANK E. HARRELL, JR.

Power Calculation for Clinical Trials When the Outcome Is a Composite Ranking
of Survival and a Nonfatal Outcome

305

JIANJIAN GONG, JOSÉ C. PINHEIRO, AND DAVID L. DEMETS

Estimating Significance Level and Power Comparisons for Testing Multiple
Endpoints in Clinical Trials

313

GILLIAN M. RAAB, SIMON DAY, AND JILL SALES

How to Select Covariates to Include in the Analysis of a Clinical Trial

330

ROSEMARIE MICK, JOHN J. CROWLEY, AND RAYMOND J. CARROLL

Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for Which Time
to Disease Progression Is the Primary Endpoint

343

MELISSA FAZZARI, GLENN HELLER, AND HOWARD I. SCHER

The Phase II/III Transition: Toward the Proof of Efficacy in Cancer Clinical Trials

360

YING QING CHEN AND MEI-CHENG WANG

Estimating a Treatment Effect with the Accelerated Hazards Models

369

Letter from the Editor

381

Letter to the Editor

381

Design Papers

MICHEL LIÈVRE, MICHEL MARRE, GILLES CHATELLIER,

PIERRE-FRANÇOIS PLOUIN, JEAN-CHRISTOPHE RÉGLIER, LINDA RICHARDSON, FRANÇOISE BUGNARD, AND DANIEL VASMANT, ON BEHALF OF THE DIABHYCAR STUDY GROUP The Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study: Design, Organization, and Patient Recruitment	383
THE RADIAL ARTERY PATENCY STUDY INVESTIGATORS Multicenter Radial Artery Patency Study (RAPS): Study Design	397
Erratum	414

Volume 21, Number 5, 2000

Original Articles

JONAS RANSTAM, MARC BUYSE, STEPHEN L. GEORGE, STEPHEN EVANS, NANCY L. GELLER, BRUNO SCHERRER, EMMANUEL LASAFFRE, GORDON MURRAY, LUTZ EDLER, JANE L. HUTTON, THEODORE COLTON, AND PETER LACHENBRUCH FOR THE ISCB SUBCOMMITTEE ON FRAUD Fraud in Medical Research: An International Survey of Biostatisticians	415
OLIVER M. BAUTISTA, RAYMOND P. BAIN, AND JOHN M. LACHIN A Flexible Stochastic Curtailing Procedure for the Log-Rank Test	428
CYNTHIA A. BRANDT, PRAKASH NADKARNI, LUIS MARENCO, BRYANT T. KARRAS, CHARLES LU, LEE SCHACTER, JOHN M. FISK, AND PERRY L. MILLER Reengineering a Database for Clinical Trials Management: Lessons for System Architects	440
CURTIS L. MEINERT, ADELE KAPLAN GILPIN, AYNUR ÜNALP, AND CHRISTOPHER DAWSON Gender Representation in Trials	462
MARIA E. SUAREZ-ALMAZOR, ELAINE BELSECK, JOANNE HOMIK, MARLENE DORGAN, AND CESAR RAMOS-REMUS Identifying Clinical Trials in the Medical Literature with Electronic Databases: MEDLINE Alone Is Not Enough	476
FUJIAN SONG, ANNE-MARIE GLENNY, AND DOUGLAS G. ALTMAN Indirect Comparison in Evaluating Relative Efficacy Illustrated by Antimicrobial Prophylaxis in Colorectal Surgery	488

Commentary

SUSAN S. ELLENBERG Fraud Is Bad, Studying Fraud Is Hard	498
--	-----

Letter to the Editor	501
----------------------	-----

Design Paper

THE HEMO STUDY GROUP, PREPARED BY: TOM GREENE, GERALD J. BECK, JENNIFER J. GASSMAN, FRANK A. GOTCH, JOHN W. KUSEK, ANDREW S. LEVEY, NATHAN W. LEVIN, GERALD SCHULMAN, AND GARABED EKNYAN Design and Statistical Issues of the Hemodialysis (HEMO) Study	502
---	-----

Erratum	526
---------	-----

**Volume 21, Number 5S, 2000
Supplement**

List of Conference Participants	v
SALLY A. SHUMAKER AND W. JACK REJESKI Preface	155S
LAWRENCE R. BRAWLEY AND S. NICOLE CULOS-REED Studying Adherence to Therapeutic Regimens: Overview, Theories, Recommendations	156S
W. JACK REJESKI, LAWRENCE R. BRAWLEY, EDWARD MCAULEY, AND STEPHEN RAPP An Examination of Theory and Behavior Change in Randomized Clinical Trials	164S
ROGER T. ANDERSON, MARCIA ORY, STUART COHEN, AND JEFFREY S. MCBRIDE Issues of Aging and Adherence to Health Interventions	171S
KRISTIN E. KIDD AND DAVID G. ALTMAN Adherence in Social Context	184S
MARA Z. VITOLINS, CYNTHIA S. RAND, STEPHEN R. RAPP, PAUL M. RIBISL, AND MARY ANN SEVICK Measuring Adherence to Behavioral and Medical Interventions	188S
KATHLEEN A. MARTIN, DEBORAH J. BOWEN, JACQUELINE DUNBAR-JACOB, AND MICHAEL G. PERRI Who Will Adhere? Key Issues in the Study and Prediction of Adherence in Randomized Controlled Trials	195S
S. NICOLE CULOS-REED, W. JACK REJESKI, EDWARD MCAULEY, JUDITH K. OCKENE, AND DEBRA L. Roter Predictors of Adherence to Behavior Change Interventions in the Elderly	200S
AURORA M. SHERMAN, DEBORAH J. BOWEN, MARA VITOLINS, MICHAEL G. PERRI, MILAGROS C. ROSAL, MARY ANN SEVICK, AND JUDITH K. OCKENE Dietary Adherence: Characteristics and Interventions	206S
DINNIE CHAO, CAPRI G. FOY, AND DEBORAH FARMER Exercise Adherence among Older Adults: Challenges and Strategies	212S
SHELLIE ELLIS, SALLY SHUMAKER, WILLIAM SIEBER, CYNTHIA RAND, AND THE PHARMACOLOGICAL INTERVENTION WORKING GROUP Adherence to Pharmacological Interventions: Current Trends and Future Directions	218S
SALLY A. SHUMAKER, ELIZABETH DUGAN, AND DEBORAH J. BOWEN Enhancing Adherence in Randomized Controlled Clinical Trials	226S
WILLIAM J. SIEBER AND ROBERT M. KAPLAN Informed Adherence: The Need for Shared Medical Decision Making	233S
CYNTHIA S. RAND AND MARY ANN SEVICK Ethics in Adherence Promotion and Monitoring	241S

**Volume 21, Number 6S, 2000
Supplement**

JOHN K. GOHAGAN Preface	249S
----------------------------	------

JOHN K. GOHAGAN, PHILIP C. PROROK, RICHARD B. HAYES, AND BARNETT S. KRAMER FOR THE PLCO PROJECT TEAM The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, Organization, and Status	251S
PHILIP C. PROROK, GERALD L. ANDRIOLE, ROBERT S. BRESALIER, SAUNDRA S. BUYS, DAVID CHIA, E. DAVID CRAWFORD, RONALD FOGEL, EDWARD P. GELMANN, FRED GILBERT, MARSHA A. HASSON, RICHARD B. HAYES, CHRISTINE COLE JOHNSON, JACK S. MANDEL, ALBERT OBERMAN, BARBARA O'BRIEN, MARTIN M. OKEN, SAMEER RAFLA, DOUGLAS REDING, WILMER RUTT, JOEL L. WEISSFELD, LANCE YOKOCHI, AND JOHN K. GOHAGAN FOR THE PLCO PROJECT TEAM Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	273S
BARBARA O'BRIEN, LEAH NICHAMAN, JOYCE E.H. BROWNE, DAVID L. LEVIN, PHILIP C. PROROK, AND JOHN K. GOHAGAN FOR THE PLCO PROJECT TEAM Coordination and Management of a Large Multicenter Screening Trial: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	310S
MARSHA A. HASSON, RICHARD M. FAGERSTROM, DALIA C. KAHANE, JUDITH H. WALSH, MAX H. MYERS, CLIFFORD CAUGHMAN, BLAINE WENZEL, JULINE C. HARALSON, LYNN M. FLICKINGER, AND LOUISA M. TURNER FOR THE PLCO PROJECT TEAM Design and Evolution of the Data Management Systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	329S
RICHARD B. HAYES, DOUGLAS REDING, WILLIAM KOPP, AMY F. SUBAR, NARAYAN BHAT, NATHANIEL ROTHMAN, NEIL CAPORASO, REGINA G. ZIEGLER, CHRISTINE COLE JOHNSON, JOEL L. WEISSFELD, ROBERT N. HOOVER, PATRICIA HARTGE, CINDY PALACE, AND JOHN K. GOHAGAN FOR THE PLCO PROJECT TEAM Etiologic and Early Marker Studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	349S
NANCY K. SIMPSON, CHRISTINE COLE JOHNSON, SHERYL L. OGDEN, EDUARD GAMITO, NINA TROCKY, COLLEEN McGUIRE, JAMAAL MARTIN, SARAH BARROW, LOIS LAMERATO, LYNN M. FLICKINGER, KAREN G. BROSKI, DEBORAH ENGELHARD, CINDY HILKE, JANET BONK, BETSY GAHAGAN, LISA H. GREN, JEFFERY CHILDS, KAREN LAPPE, MONA FOUAD, JOANICE THOMPSON, AND DOROTHY SULLIVAN FOR THE PLCO PROJECT TEAM Recruitment Strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The First Six Years	356S
FRED L. STALLINGS, MARVELLA E. FORD, NANCY K. SIMPSON, MONA FOUAD, JAN C. JERNIGAN, JEANETTE M. TRAUTH, AND DANIEL S. MILLER FOR THE PLCO PROJECT TEAM Black Participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	379S
JOEL L. WEISSFELD, RICHARD M. FAGERSTROM, AND BARBARA O'BRIEN FOR THE PLCO PROJECT TEAM Quality Control of Cancer Screening Examination Procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	390S
ANTHONY B. MILLER, SUSAN YURGALEVITCH, AND JOEL L. WEISSFELD FOR THE PLCO PROJECT TEAM Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial	400S

Original Articles

- MICHAEL A. PROSCHAN AND MYRON A. WACLAWIW
Practical Guidelines for Multiplicity Adjustment in Clinical Trials 527
- EMMANUEL LESAFFRE AND ERIK DE KLERK
Estimating the Power of Compliance—Improving Methods 540
- F.Y. HSIEH AND PHILIP W. LAVORI
Sample-Size Calculations for the Cox Proportional Hazards Regression Model
with Nonbinary Covariates 552
- JIANDONG LU AND THOMAS F. PAJAK
Statistical Power for a Long-Term Survival Trial with a Time-Dependent
Treatment Effect 561
- ANNA T.R. LEGEDZA AND JOSEPH G. IBRAHIM
Longitudinal Design for Phase I Clinical Trials Using the Continual
Reassessment Method 574

Letter to the Editor 589

Book Review 593

Design Paper

- DIEDERIK VAN DIJK, ARNO P. NIERICH, FRANK D. EEFTING, ERIK BUSKENS,
HENDRIK M. NATHOE, ERIK W.L. JANSEN, CORNELIUS BORST,
JOHANNES T.A. KNAPE, JOHAN J. BREDÉE, ETIENNE O. ROBLES DE MEDINA,
DIEDERICK E. GROBBEE, JAN C. DIEPHUIS, AND PETER P.TH. DE JAEGERE
The Octopus Study: Rationale and Design of Two Randomized Trials on
Medical Effectiveness, Safety, and Cost-Effectiveness of Bypass Surgery on the
Beating Heart 595

Author Index 610

Subject Index 612

Volume Contents 623